Hikma Pharmaceuticals Rating Reiterated by JPMorgan Chase & Co. (HIK)
Hikma Pharmaceuticals (LON:HIK)‘s stock had its “overweight” rating reiterated by stock analysts at JPMorgan Chase & Co. in a report issued on Wednesday, American Banking and Market News reports.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays Capital reiterated an “overweight” rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note to investors on Monday. They now have a GBX 1,270 ($20.17) price target on the stock. Separately, analysts at UBS AG reiterated a “neutral” rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note to investors on Thursday, August 22nd. They now have a GBX 1,050 ($16.67) price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note to investors on Wednesday, August 21st. They now have a GBX 1,250 ($19.85) price target on the stock, up previously from GBX 1,200 ($19.05).
Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of GBX 1,143.46 ($18.16).
Shares of Hikma Pharmaceuticals (LON:HIK) traded up 0.88% on Wednesday, hitting GBX 1036.00. 264,586 shares of the company’s stock traded hands. Hikma Pharmaceuticals has a 52 week low of GBX 714.50 and a 52 week high of GBX 1128.00. The stock’s 50-day moving average is GBX 1066. and its 200-day moving average is GBX 1010.. The company’s market cap is £2.048 billion.
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.